Rudy Paladini
Biotech professional with extensive experience in the discovery, pharmacology and development of small molecule and biological therapeutics and their translational implications
Halo is focused on creating first-in-class, disease-modifying therapies using innovative approaches to edit the extracellular matrix (ECM). We are exploiting novel insights in ECM biology by selectively editing its components to restore homeostasis in diseases affected by inflammation and fibrosis. Our lead program is aimed to deliver a first in class disease-modifying therapy for pulmonary hypertension.
